Immunotherapy of COVID-19 With B-Cell Activating CPI-006 Monoclonal Antibody
Latest Information Update: 28 Sep 2021
At a glance
- Drugs Mupadolimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Corvus Pharmaceuticals
- 21 Sep 2021 Results published in the medRxiv
- 11 Jun 2021 Planned primary completion date changed from 31 Mar 2021 to 18 Jul 2021.
- 25 Mar 2021 Status changed from recruiting to completed, according to a Corvus Pharmaceuticals media release.